Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared on LinkedIn:
“Comprehensive biomarker analysis through NGS-based assays is transforming cancer care but many in the community still face barriers like limited infrastructure and inconsistent reimbursement, keeping precision medicine out of reach
Join me and Dr. Song as we dive into real-wolrd strategies to close this gap.”
